Boston Scientific Ramping Up Internal R&D; Medinol Claims Infringement
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's R&D spending is expected to jump roughly 16% to $230 mil. in 2001, reflecting the firm's increased commitment to in-house innovation as opposed to relying primarily on acquisitions to build its product pipeline.
You may also be interested in...
Alternative Stent Supply Agreement Violated By Medinol - BSX Countersuit
Boston Scientific is charging Israeli stent partner Medinol with violating their supply agreement by failing to provide chemical etching services that would benefit an alternative stent line sanctioned by the deal.
Alternative Stent Supply Agreement Violated By Medinol - BSX Countersuit
Boston Scientific is charging Israeli stent partner Medinol with violating their supply agreement by failing to provide chemical etching services that would benefit an alternative stent line sanctioned by the deal.
Boston Scientific Express Stent Potentially Threatened By Medinol Lawsuit
Boston Scientific's strategy to rely on its internally developed Express coronary stent platform as a viable alternative to a troubled relationship with stent partner Medinol may be jeopardized by the Israeli firm's April 5 lawsuit alleging that the Express R&D initiative constituted breach of contract by Boston Scientific.